PE20151155A1 - Derivados de carbamato/urea - Google Patents

Derivados de carbamato/urea

Info

Publication number
PE20151155A1
PE20151155A1 PE2015000045A PE2015000045A PE20151155A1 PE 20151155 A1 PE20151155 A1 PE 20151155A1 PE 2015000045 A PE2015000045 A PE 2015000045A PE 2015000045 A PE2015000045 A PE 2015000045A PE 20151155 A1 PE20151155 A1 PE 20151155A1
Authority
PE
Peru
Prior art keywords
carbamate
urea derivatives
pyridazine
cyano
alkenyl
Prior art date
Application number
PE2015000045A
Other languages
English (en)
Spanish (es)
Inventor
Mark Gary Bock
Yves Auberson
Dario Braga
Marco Curzi
Stephanie Kay Dodd
Stefano Luca Giaffreda
Haiyang Jiang
Piotr H Karpinski
Thomas J Troxler
Tielin Wang
Xiaoyang Wang
Xuechun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20151155A1 publication Critical patent/PE20151155A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2015000045A 2012-07-20 2013-07-18 Derivados de carbamato/urea PE20151155A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28

Publications (1)

Publication Number Publication Date
PE20151155A1 true PE20151155A1 (es) 2015-08-05

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000045A PE20151155A1 (es) 2012-07-20 2013-07-18 Derivados de carbamato/urea

Country Status (41)

Country Link
US (4) US9034874B2 (en:Method)
EP (1) EP2875016B1 (en:Method)
JP (1) JP6203841B2 (en:Method)
KR (1) KR102150739B1 (en:Method)
CN (1) CN104470911B (en:Method)
AP (1) AP3710A (en:Method)
AR (1) AR092354A1 (en:Method)
AU (1) AU2013291617B2 (en:Method)
BR (1) BR112015001207B1 (en:Method)
CA (1) CA2878006C (en:Method)
CL (1) CL2015000056A1 (en:Method)
CO (1) CO7170173A2 (en:Method)
CR (1) CR20150019A (en:Method)
CU (1) CU24248B1 (en:Method)
CY (1) CY1119492T1 (en:Method)
DK (1) DK2875016T3 (en:Method)
EA (1) EA026091B1 (en:Method)
ES (1) ES2648512T3 (en:Method)
GT (1) GT201500012A (en:Method)
HR (1) HRP20171692T1 (en:Method)
HU (1) HUE035592T2 (en:Method)
IL (1) IL236656A (en:Method)
IN (1) IN2014DN10449A (en:Method)
JO (1) JO3439B1 (en:Method)
LT (1) LT2875016T (en:Method)
MX (1) MX362059B (en:Method)
MY (1) MY168752A (en:Method)
NO (1) NO2875016T3 (en:Method)
NZ (1) NZ702346A (en:Method)
PE (1) PE20151155A1 (en:Method)
PH (1) PH12014502743B1 (en:Method)
PL (1) PL2875016T3 (en:Method)
PT (1) PT2875016T (en:Method)
RS (1) RS56479B1 (en:Method)
SG (2) SG10201700188PA (en:Method)
SI (1) SI2875016T1 (en:Method)
TN (1) TN2014000497A1 (en:Method)
TW (1) TWI597276B (en:Method)
UY (1) UY34921A (en:Method)
WO (1) WO2014013469A1 (en:Method)
ZA (1) ZA201408805B (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
BR112021006366A2 (pt) 2018-10-11 2021-07-06 Novartis Ag uso de um agonista inverso h3r para o tratamento de sonolência diurna excessiva associada à doença de parkinson (dp)
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
TW301607B (en:Method) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
ATE327230T1 (de) 2000-01-20 2006-06-15 Eisai Co Ltd Piperidinverbindungen und diese enthaltenden medikamente
CN1298715C (zh) 2001-03-13 2007-02-07 先灵公司 作为组胺h3拮抗剂的非咪唑化合物
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7592347B2 (en) 2003-04-23 2009-09-22 Glaxo Group Limited Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
EP1717230B1 (en) 2004-02-13 2014-08-06 Msd K.K. Fused-ring 4-oxopyrimidine derivative
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
EP1784398A1 (en) 2004-09-02 2007-05-16 Teva Pharmaceutical Industries Ltd Purification of olmesartan medoxomil
CN1993355A (zh) 2004-09-02 2007-07-04 特瓦制药工业有限公司 奥美沙坦酯的纯化方法
JP2009506987A (ja) * 2005-08-02 2009-02-19 ニューロゲン コーポレイション ジピペラジニルケトンおよび関連する類似体
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
BRPI0820950A2 (pt) * 2007-12-05 2015-07-07 Astrazeneca Ab Composto, formulação farmacêutica, uso de um composto, métodos para o tratamento ou prevenção de condições ou doenças e para inibição da angiogênese, e, processo para a preparação de um composto.
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2011090062A1 (ja) 2010-01-22 2011-07-28 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
KR20150036081A (ko) 2015-04-07
HUE035592T2 (en) 2018-05-28
CA2878006C (en) 2020-10-27
EA026091B1 (ru) 2017-02-28
US20140163036A1 (en) 2014-06-12
ZA201408805B (en) 2016-08-31
ES2648512T3 (es) 2018-01-03
EP2875016A1 (en) 2015-05-27
SI2875016T1 (sl) 2017-11-30
WO2014013469A1 (en) 2014-01-23
TN2014000497A1 (en) 2016-03-30
TWI597276B (zh) 2017-09-01
IN2014DN10449A (en:Method) 2015-08-21
US9273026B2 (en) 2016-03-01
EA201590250A1 (ru) 2015-05-29
CY1119492T1 (el) 2018-03-07
AU2013291617B2 (en) 2015-10-01
CR20150019A (es) 2015-05-04
US20150218127A1 (en) 2015-08-06
DK2875016T3 (da) 2017-11-27
UY34921A (es) 2014-02-28
MY168752A (en) 2018-11-30
US20170275264A1 (en) 2017-09-28
CN104470911A (zh) 2015-03-25
US9624192B2 (en) 2017-04-18
JP2015522606A (ja) 2015-08-06
SG10201700188PA (en) 2017-02-27
TW201408656A (zh) 2014-03-01
AU2013291617A1 (en) 2015-01-15
CO7170173A2 (es) 2015-01-28
IL236656A0 (en) 2015-02-26
RS56479B1 (sr) 2018-01-31
LT2875016T (lt) 2017-11-10
US9034874B2 (en) 2015-05-19
GT201500012A (es) 2017-11-09
MX362059B (es) 2019-01-07
SG11201408020RA (en) 2015-03-30
PL2875016T3 (pl) 2018-01-31
BR112015001207B1 (pt) 2022-08-09
PH12014502743A1 (en) 2015-02-02
CA2878006A1 (en) 2014-01-23
PT2875016T (pt) 2017-11-30
CL2015000056A1 (es) 2015-03-20
MX2015000903A (es) 2015-04-10
AP2014008109A0 (en) 2014-12-31
CN104470911B (zh) 2018-04-06
BR112015001207A2 (pt) 2017-08-01
JP6203841B2 (ja) 2017-09-27
KR102150739B1 (ko) 2020-09-02
PH12014502743B1 (en) 2015-02-02
IL236656A (en) 2017-12-31
CU24248B1 (es) 2017-02-02
AR092354A1 (es) 2015-04-15
HK1204609A1 (en) 2015-11-27
HRP20171692T1 (hr) 2017-12-15
NZ702346A (en) 2017-06-30
AP3710A (en) 2016-05-31
EP2875016B1 (en) 2017-08-23
US20160244426A1 (en) 2016-08-25
NO2875016T3 (en:Method) 2018-01-20
BR112015001207A8 (pt) 2018-01-16
JO3439B1 (ar) 2019-10-20
CU20150006A7 (es) 2016-02-29

Similar Documents

Publication Publication Date Title
PE20151155A1 (es) Derivados de carbamato/urea
PE20171306A1 (es) Derivados de quinazolina utilizados para tratar el vih
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
CR20140084A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
EA201591457A8 (ru) Терапевтические соединения
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
DE602008000754D1 (de) Tropanverbindungen
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
PH12014500814A1 (en) New aryl-quinoline derivatives
EA201190293A1 (ru) Пролекарства триптолида
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
UA114325C2 (uk) Феноксіетилпіперидинові сполуки
BR112014009108A2 (pt) derivado heterocíclico tendo atividade antagonista de receptor de pgd2
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
ECSP088257A (es) Derivados de amida
NI201100051A (es) Sales de n - [ 6 - ( cis - 2, 6 - dimetil - morfolin - 4 - il ) - piridin - 3 - il ] - 2 - metil - 4' - ( trifluoro - metoxi ) - [ 1, 1' - bifenil] - 3 - carboxamida.
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
EA201290229A1 (ru) Производные спиролактама и их применение
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório

Legal Events

Date Code Title Description
FG Grant, registration